Anti-Rheumatic Rx
Dr. Rachel Tate uptoTate
4 years 11 months ago
Both fat mass and fat free mass have an impact on the response to bDMARDs after 6 months of treatment in AS pts. No tx response changes w/ skeletal muscle mass, visceral fat as well as water components. #ABS1376 #ACR20 @RheumNow https://t.co/oIdE8qvJPp https://t.co/wlXFf8esey
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
Richard Conway RichardPAConway
4 years 11 months ago
Dr Lee reports on risk of melanoma and NMSC risk in RA in cohort study using propensity score matching. No difference in risk between MTX and HCQ overall. Increase BCC in MTX (HR 1.32) but less SCC (HR 0.77) @rheumnow #ACR20 Abstr#1001 https://t.co/LDWgfGK9LS
COVID and Rheumatic Disease Patients: Dr. Kevin Winthrop
Portland-based Dr. Kevin Winthrop from OHSU discusses Saturday ACR 2020 posters #0623 and #0629 related to COVID-19 and RA patients.
Subclinical Synovitis: Dr Eric Dein
Dr. Eric Dein reviews abstract #0481 presented at the 2020 ACR annual meeting, and reviews the Twitter poll he posted on whether clinicians would start DMARDs in this scenario.
HCQ and QTc in RA and SLE Patients: Dr. Kathryn Dao
Dr. Kathryn Dao reviews abstract #0431 presented at the 2020 ACR annual meeting.
Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews.
Click here to listen.
Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews.
Click here to listen.
Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews.
Click here to listen.
Content covered includes:
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Dr. Antoni Chan synovialjoints
4 years 11 months ago
Etanercept monotherapy significantly more effective than Methotrexate monotherapy in maintaining remission in RA patients on combination therapy. Data from the SEAM-RA study @RheumNow #ACR20 Abstr#0939 #ACRbest
Robert B Chao, MD doctorRBC
4 years 11 months ago
Racial disparity in SSc-ILD pts treated with MMF?
1️⃣Early initiation of MMF significantly slowed ⬇️ of FVC%
2️⃣No difference in MMF efficacy between African-Americans and non-AA
3️⃣AA had baseline lower FVC%
@RheumNow #ACR20 Abs0929 https://t.co/rtsbe7OCvA
The Lancet Rheumatology TheLancetRheum
4 years 11 months ago
Editors Pick for #ACR20—Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial https://t.co/cunDxVl5XG https://t.co/OGItXCuWDI
Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety.
k dao KDAO2011
4 years 11 months ago
HCQ might decrease risk for NAFLD!
Restrospective study of 5600 pts noted patients on HCQ (despite having more metabolic syndrome, HTN, DM) had 24% less incidence of NAFLD compared to pts not on HCQ
Abstr#0177 #ACR20 @rheumnow
https://t.co/ZoK2aC0ZQR
Poster Hall